SB02024, developed by Sprint Bioscience together with SAR-405 by Sanofi Pharma revealed that inhibition of Vps34 attenuated tumor growth and extended survival in multiple pre-clinical models (Noman et al., 2020). Here, PIK3C3 is linked to neoplasm.